Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies
Authors
Keywords
-
Journal
EXPERIMENTAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-01-16
DOI
10.1111/exd.14750
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases
- (2022) Misato Ito et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunogenic cell stress and death
- (2022) Guido Kroemer et al. NATURE IMMUNOLOGY
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- High expression of CD28 enhanced the anti-cancer effect of siRNA-PD-1 through prompting the immune response of melanoma-bearing mice
- (2022) Huijie Jia et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
- (2022) Alexander C. Huang et al. NATURE IMMUNOLOGY
- Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1–Resistant Melanoma
- (2022) Julia M. DeRogatis et al. Cancer Immunology Research
- B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade
- (2022) Shubhra Singh et al. Frontiers in Immunology
- Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
- (2022) Angela Pizzolla et al. Journal for ImmunoTherapy of Cancer
- Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1
- (2022) Julien Rossignol et al. iScience
- Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
- (2022) Alexander N. Shoushtari et al. CLINICAL CANCER RESEARCH
- Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells
- (2022) Gary Shaw et al. Journal of Hematology & Oncology
- Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
- (2022) Elisabeth Livingstone et al. LANCET
- Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma
- (2022) Hongbin Wang et al. MOLECULAR PHARMACEUTICS
- Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
- (2022) Jing Yu et al. Frontiers in Pharmacology
- Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
- (2022) Rick D Vavolizza et al. Journal for ImmunoTherapy of Cancer
- Melanoma surgery—An update
- (2022) Uwe Wollina Dermatologic Therapy
- Oncolytic adenovirus ORCA-010 activates pro-inflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma
- (2021) Ioanna Emilova Milenova et al. HUMAN GENE THERAPY
- Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
- (2021) Sadna Budhu et al. Cell Reports
- Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
- (2021) Anastasia Prokopi et al. Journal for ImmunoTherapy of Cancer
- A MyD88/IL-1R axis regulates PD-1 expression on tumor-associated macrophages and sustains their immunosuppressive function in melanoma
- (2021) Sarang Tartey et al. CANCER RESEARCH
- Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
- (2021) Julia Boshuizen et al. CANCER RESEARCH
- Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment.
- (2021) Tan-Trieu Nguyen et al. CLINICAL CANCER RESEARCH
- Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion
- (2021) Isak W. Tengesdal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
- (2021) Diwakar Davar et al. SCIENCE
- Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
- (2021) Hai-Jun Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses
- (2021) Fan Huang et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade
- (2021) Yu-Ju Tseng et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
- (2021) Anne Montfort et al. Cancer Immunology Research
- Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- (2021) Yujue Wang et al. CANCER CELL
- AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma
- (2021) Keitaro Fukuda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
- (2021) Nicolas Jacquelot et al. NATURE IMMUNOLOGY
- The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
- (2021) Lars Ny et al. Nature Communications
- Overcoming PD-1 Blockade Resistance With CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients With Metastatic Melanoma
- (2021) Antoni Ribas et al. Cancer Discovery
- STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
- (2021) Takashi Nakamura et al. Journal for ImmunoTherapy of Cancer
- SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis
- (2021) Satoru Yokoyama et al. CANCER RESEARCH
- Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma
- (2021) Bixia Tang et al. EUROPEAN JOURNAL OF CANCER
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
- (2020) Caroline Imbert et al. Nature Communications
- Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity
- (2020) Christopher E. Rudd et al. Cell Reports
- Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
- (2020) Anne Fröhlich et al. EBioMedicine
- Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma
- (2020) Pedro Miguel Lacal et al. PHARMACOLOGICAL RESEARCH
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma
- (2020) Mona Yazdani et al. VACCINE
- Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
- (2020) Jo Waaler et al. Communications Biology
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
- (2020) Patrick A. Ott et al. CELL
- Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
- (2020) Daniela Cerezo-Wallis et al. NATURE MEDICINE
- Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype
- (2020) Ashvin R. Jaiswal et al. Cancer Immunology Research
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- (2020) Erez N. Baruch et al. SCIENCE
- Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma
- (2019) Saeed Daneshmandi et al. Cancers
- Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti–PD-1 in melanoma
- (2019) Laurene S. Cheung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy
- (2019) Takashi Inozume et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
- (2019) Rui-Yan Wu et al. CLINICAL CANCER RESEARCH
- A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab
- (2019) Thilo Gambichler et al. JOURNAL OF IMMUNOTHERAPY
- CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
- (2019) Weimin Wang et al. NATURE
- Decline of PD ‐1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade
- (2019) T. Gambichler et al. BRITISH JOURNAL OF DERMATOLOGY
- m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
- (2019) Seungwon Yang et al. Nature Communications
- Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone
- (2019) David Rafei-Shamsabadi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
- (2019) Jiayi Yu et al. CLINICAL CANCER RESEARCH
- Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators
- (2019) João Conniot et al. Nature Nanotechnology
- TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma
- (2019) Alisha Holtzhausen et al. Cancer Immunology Research
- Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
- (2019) Sathya Muralidhar et al. CANCER RESEARCH
- TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
- (2019) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model
- (2019) Khanidtha Chitphet et al. ACS Biomaterials-Science & Engineering
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma
- (2018) Sun-Hee Kim et al. CLINICAL CANCER RESEARCH
- Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota
- (2018) Mengxue Dong et al. Cell Death & Disease
- Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
- (2017) Paola Falletta et al. GENES & DEVELOPMENT
- Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
- (2017) Sun Hye Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- PSGL-1: A New Player in the Immune Checkpoint Landscape
- (2017) Roberto Tinoco et al. TRENDS IN IMMUNOLOGY
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation
- (2016) Tomonori Yaguchi et al. INTERNATIONAL IMMUNOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- (2015) L. Corrales et al. CLINICAL CANCER RESEARCH
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/ -Catenin Signaling in Human Melanoma Cells
- (2012) T. Yaguchi et al. JOURNAL OF IMMUNOLOGY
- GSK3β Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation
- (2012) Jobin K. John et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now